Overview
- Cipla said on Thursday that consolidated net profit for Q1 FY27 fell about 39% year on year to roughly ₹789 crore while total revenue rose modestly to about ₹7,119 crore.
- Operating profit shrank sharply as EBITDA fell about 33% to ₹1,192 crore and EBITDA margin contracted to 16.7% from 25.6% a year earlier, driven by a near 15% rise in total expenses.
- The company restated comparatives after it began reporting a single operating segment following a change in the chief operating decision maker and reclassified some marketing costs as a reduction from revenue, which it says did not affect profit or cash flow.
- Cipla reported a 21% drop in North America sales to about ₹1,532 crore while its One‑India business grew around 12% to ₹3,452 crore, and EPS improved sequentially from the previous quarter to ₹9.77.
- Management named Dinesh Jain as global CFO effective July 24 and said the proposed merger with wholly owned subsidiary Inzpera Healthsciences remains subject to National Company Law Tribunal approval, factors investors will watch next.